Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a Phase II study.

Westin JR, Phillips TJ, Mehta A, Hoffmann MS, Gonzalez-Barca E, Thieblemont C, Bastos-Oreiro M, Greil R, Giebel S, Wei MC, Wang J, Bucher R, Sit J, Penuel E, Purev E, Yee DL, Bergua Burgues JM.

Blood Adv. 2025 Feb 5:bloodadvances.2024014907. doi: 10.1182/bloodadvances.2024014907. Online ahead of print. PMID: 3990848.

https://pubmed.ncbi.nlm.nih.gov/39908481/